ipid changes in patients with active ulcerative colitis treated with either tofacitinib or infliximab
- Conditions
- lcerative colitisLipidsTofacitinibInfliximab
- Registration Number
- NL-OMON23533
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
aged 18 years or older
- previous diagnosis with ulcerative colitis (UC) of at least 3 months
Exclusion Criteria
- absence written informed consent
- imminent need for in-hospital treatment
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in HDL- and LDL-cholesterol concentrations after tofacitinib and infliximab induction therapy of 8 weeks
- Secondary Outcome Measures
Name Time Method